The latest price target for Insmed (NASDAQ:INSM) was reported by JP Morgan on June 8, 2026. The analyst firm set a price target for $179.00 expecting INSM to rise to within 12 months (a possible 88.52% upside). 75 analyst firms have reported ratings in the last year.

The latest analyst rating for Insmed (NASDAQ:INSM) was provided by JP Morgan, and Insmed maintained their overweight rating.

The last upgrade for Insmed Inc happened on March 30, 2026 when Morgan Stanley raised their price target to $212. Morgan Stanley previously had an equal-weight for Insmed Inc.

The last downgrade for Insmed Inc happened on August 13, 2025 when Morgan Stanley changed their price target from $112 to $126 for Insmed Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Insmed, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Insmed was filed on June 8, 2026 so you should expect the next rating to be made available sometime around June 8, 2027.

While ratings are subjective and will change, the latest Insmed (INSM) rating was a maintained with a price target of $180.00 to $179.00. The current price Insmed (INSM) is trading at is $94.95, which is out of the analyst’s predicted range.